Status: Recruiting
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
The aim of this clinical trial is to assess the feasibility, safety, and efficacy of CAR-T cell therapy targeting multiple cancer cell antigens in high-risk multiple myeloma or plasmacytoma as part of a frontline treatment regimen for patients. Another goal of the study is to learn more about the persistence and function of these CAR-T cells in the body.
Participants needed: 20
Trial details
Phase: Phase 1, Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Shenzhen Geno-Immune Medical InstituteUpdated: Jun 23, 2026Locations: 1
Eligibility criteria
Male and female subjects with multiple myeloma or plasmacytoma [+5]
Pregnant or lactating women [+4]